The new generation of antiepileptic drugs: Advantages and disadvantages

British Journal of Clinical Pharmacology

Volumn 42, Issue 5, 1996, Pages 531-543

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

antiepileptic drugs; felbamate; gabapentin; lamotrigine; oxcarbazepine; tiagabine; topiram ate; vigabatrin; zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATIN; ZONISAMIDE;

APLASTIC ANEMIA; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0029826744     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00046.x     Document Type: Review

References (76)

1. Richens A, Perucca E. Clinical pharmacology and medical treatment. In A Textbook of Epilepsy, eds. Laidlaw J, Richens A, Chadwick D, editors. Edinburgh: Churchill-Livingstone, 1993: 495-559.
2. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-175.
3. Perucca E. Principles of drug treatment. In The Treatment of Epilepsy, eds. Shorvon S, Dreifuss F, Fish DF, Thomas D, Blackwell Science, Ltd. Oxford, 1996: 152-168.
4. Pisani F, Perucca E, Avanzini G, Richens A. New antiepileptic drugs. Amsterdam: Elsevier, 1991
5. Perucca E. The clinical pharmacology of the new antiepileptic drugs. Pharmacol Res 1993; 28: 89-106.
6. Perucca E. Recipes for clinical practice. In An appraisal of some new anticonvulsants-a clinical perspective, ed. Trimble M.R., John Wiley and Sons, Chichester, 1994, pp. 145-160.
7. Beghi E, Perucca E. The management of epilepsy in the 1990s. Acquisitions, uncertainties and perspectives for future research. Drugs 1995; 49: 680-694.
8. Porter RJ, Rogawski MA. New antiepileptic drugs: from serependity to rational discovery. Epilepsia 1992; 33 (suppl. 1):Sl-6.
9. Upton N. Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings. Trends Pharmacol Sci 1994; 15: 456-463.
10. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993; 612: 190-199.
11. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, van der Geest P. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neural 1983; 40: 797-802.
12. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 445.
13. Stolarek I, Blacklaw J, Thompson GG, Brodie MJ. Gamma-vinyl GABA (vigabatrin) and lamotrigine: Synergism in refractory epilepsy? Epilepsia 1993; 34 (suppl. 2): 108-109.
14. Leach JP, Brodie MJ. Lamotrigine. Clinical use. In Antiepileptic drugs, eds. Levy RH, Mattson RH. Meldrum BS, Raven Press, New York, 1995: 889-895.
15. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neural Scand 1995; 162 (suppl): 31-34.
16. Pisani, F, Di Pern, R, Perucca, E, Richens, A. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 1224.
17. Pisani, F, Oteri, G, Russo, M, et al. Effects of lamotrigine-valproate comedication on seizure frequency and upper limb tremor: A pharmacodynamic interaction? Epilepsia , 1995; 36 (suppl 3): 264.
18. Perucca E, Pisani F. Pharmacokinetics and interactions of the new antiepileptic drugs. In New antiepileptic drugs, eds. Pisani F, Perucca E, Avanzini G, Richens A, Elsevier: Amsterdam 1991: 79-88.
19. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979; 4: 153-169.
20. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J din Pharmacol 1992; 33: 611-615
21. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 1988; 15: 367-389.
22. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-427.
23. Richens A. Clinical pharmacokinetics of gabapentin. In New trends in epilepsy management, ed Chadwick D, London, Royal Society of Medicine Services Ltd, 1993: 41-46.
24. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zomisomide and tiagabine. Clin Pharmacokinet 1996; 31: 29-46.
25. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-888.
26. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
27. Perucca E, Richens A. Biotfansformation. In Antiepileptic drugs, eds. Levy RH, Mattson RH, Meldrum B, IV Edition, Raven Press, New York, 1995: 31-50.
28. Rey E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267-278.
29. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443.
30. Timmings PL, Richens A. Lamotrigine in primary generalized epilepsy. Lancet 1992; 339: 1300-1301.
31. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
32. Henry TR, Leppik IE, Gumnit RJ, Jacobs MP. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988; 38: 928-931.
33. Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs. Zonisamide. In Antiepileptic drugs, eds. Levy RH, Mattson RH. Meldrum BS, Raven Press, New York, 1995: 1011-1023.
34. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engt J Med 1993; 328: 29-33.
35. Leppik IE, Wolff DL. The place of felbamate in the treatment of epilepsy. CNS Drugs 1995; 4: 294-301.
36. Reife RA, Pledger GW. Clinical efficacy of topiramate: U.S. and European experience. Adv AED Ther 1995; 1: 17-23.
37. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176.
38. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36 (suppl 6): 14-21.
39. Chiron C, Dumas C, Dulac O, et al. Vigabatrin versus hydrocortisone as first-line monotherapy in infantile spasms due to tuberous sclerosis. Epilepsia 1995 (suppl 3): 265.
40. Vigevano F, Cilio MR, Fabri A, Gisondi A, Cusmai R. Vigabatrin versus ACTH in treatment of infantile spasms. Epilepsia 1995; 36 (suppl 3): 265.
41. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neural 1992; 32: 393-394.
42. Dam M, Gram L, Mumford JP. Design of clinical trials of new antiepileptic drugs. In Antiepileptic drugs, eds. Levy RH, Mattson RH. Meldrum BS, Raven Press, New York, 1995: 111-122.
43. Leber P. Hazards of inference. The active control investigation. Epilepsia 1989; 30: 57-63.
44. Richens A, Yuen WC. Overview of the clinical efficacy of lamotrigine. Epilepsia 1991; 32 (suppl 2): 13-16.
45. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for addon treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res 1993; 15: 67-73.
46. Chadwick D, Marson T, Kadir Z. The clinical use of new antiepileptic drugs. An overview of safety and efficacy. Epilepsia 1996 (in press).
47. Richens A. Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J 1975; 4: 255-256.
48. Gram L, Wulff K, Rasmussen KE, et al. Valproate sodium: A controlled clinical trial including monitoring of drug levels. Epilepsia 1977; 18: 141-147.-
49. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: Lancet 1995; 345: 476-479.
50. Steiner TJ, Silveira C, Yuen AWC and the North Thames Lamictal Study Group. Comparison of lamotrigine (Lamictal) and phenytoin in newly diagnosed epilepsy. Epilepsia 1994; 35 (suppl 7): 61.
51. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: A randomized controlled study. Arch Neurol 1995: 52: 989-996
52. Dam M, Ekberg R, Lovning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76.
53. Vickery BG, Hays RD, Engel J, et al. Outcome asessment for epilepsy surgery: The impact of measuring healthrelated quality of life. Ann Neurol 1995; 37: 158-166.
54. Walker MC, Li LM, Sander JWAS. The long-term use of lamotrigine and vigabatrin: An audit of use. Br Med J 1996 (in press).
55. Reife RA, Pledger GW. Safety of topiramate in clinical use. Adv AED Ther 1995; 1: 24-29.
56. Perucca E. Anticonvulsant drugs. In Aronson JJ, Van Boxtel, CJ, eds. Side effects of drugs annual 18, Elsevier Science B.V., Amsterdam, 1994: 60-78.
57. Perucca E, Hedges A, Makki KA, et al. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 18: 401-410.
58. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33: 139-144.
59. Tartara, A, Galimberti ÇA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients. Br J Clin Pharmacol 1991; 32: 335-340.
60. Perucca E, Hebdige S, Frigo GM, et al. Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28: 779-789.
61. Pisani F, Perucca E, Di Perri R. Clinically relevant antiepileptic drug interactions. J Int Med Res 1990; 18:1-15.
62. Bartoli A, Gatti G, Barzaghi N, et al. Vigabatrin does not affect in vivo parameters of enzyme induction in humans. Epilepsia 1995; 36 (suppl 3): 162.
63. Mawer GE, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995; 68: 209-231.
64. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36 (suppl 6): 7-9.
65. Doose DR. Gisclon LG, Liao S, et al. Pharmacokinetics of topiramate. Adv AED Ther 1995; 1: 7-16.
66. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-787.
67. Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-1065.
68. Saano V, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995; 58: 523-531.
69. Brodie MJ. Therapeutic drug monitoring: An obsolete tool with the new drugs? Epilepsia 1995; 36 (suppl 3): 220.
70. Perucca E. Rational drug selection in adults. Epilepsia 1995; 36 (suppl 3): 89.
71. Schmidt D, Gram L Monotherapy versus polytherapy in epilepsy: A reappraisal. CNS Drugs 1995; 3: 194-208.
72. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. Br Med J 1978; 1: 474-476.
73. Bebin M, Black TP. New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 1994; 48: 153-171.
74. Pisani F, Gallitto G, Di Perri R. Could lamotrigine be useful in status epilepticus? A case report. J Neural Neurosurg Psych 1991; 54: 845-846.
75. Lindhout D, Omtzigt JGC. Teratogenic effects od antiepileptic drugs: Implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35 (suppl 4): S19-S28
76. Tatum WO, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45: 1216-1217.